A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure)
Primary Purpose
Hypertension
Status
Terminated
Phase
Phase 1
Locations
Netherlands
Study Type
Interventional
Intervention
LY3322207
Placebo
Sponsored by

About this trial
This is an interventional basic science trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Healthy males, as determined by medical history and physical examination, must agree to use a medically appropriate method of birth control and agree not to donate sperm from start of dosing until 90 days beyond last dose
Healthy females, as determined by medical history and physical examination, of non-child bearing potential due to:
- Menopause: spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications that induced the amenorrhea (for example: oral contraceptives, hormones, gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators, or chemotherapy)
- Surgical sterilization
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow site specific study procedures
- Have a Body Mass Index (BMI) 18 to 30 kilogram per square meter (kg/m²) at entry
- Have clinical laboratory test results within normal reference range for the population or site, or results with acceptable deviations that are judged not clinically significant
- Be 18 to 55 years old for either Part A or Part B of the study, or 18 to 65 years old for Part C only
- For Part C: must have been treated with a stable dose of ACE-I or ARB for at least 1 month
Exclusion Criteria:
- Are currently enrolled in, or discontinued within the last 60 days from, a clinical trial involving an investigational drug that has not received regulatory approval
- Have previously completed or withdrawn from this study or any other study investigating this study drug
- Have a history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, significant atopy, or any clinically significant laboratory abnormality that would preclude study participation
- Have abnormality in the 12-lead electrocardiogram (ECG) which increases study risk
- Have confirmed QT interval corrected by Bazett's method (QTcB) or Fridericia's (QTcF) method >450 millisecond (msec) for men and >470 msec for women
- Have prior Q-wave myocardial infarction or other, specific heart abnormalities, arrhythmias or fibrillations
- Have an abnormal blood pressure (supine) defined as diastolic blood pressure greater than (>)95 or less than (<)50 millimeters of mercury (mmHg) and/or systolic blood pressure >160 or <90 mmHg
- Show evidence of human immunodeficiency virus (HIV), hepatitis C, or hepatitis B
- Have donated blood of more than 100 mL (milliliters) within the last month
- Are unwilling to stop alcohol consumption while resident in the Clinical Research Unit
- Have an average weekly alcohol intake that exceeds 21 units per week (1 unit equal to (=) 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
- Have an abnormal blood pressure (supine) defined as diastolic blood pressure >95 or <50 mmHg and/or systolic blood pressure >160 or <90 mmHg
- Have serum potassium outside normal range
- Have had lymphoma, leukemia, or any malignancy within the past 5 years
- Have clinically significant multiple or severe drug allergies or intolerance
- Are lactating women
- Positive findings for known drugs of abuse
- Have received treatment with biologic agents within 3 months or 5 half-lives prior to dosing
- Participation in any other clinical trial involving a study drug or off-label use of a drug or device, or any other type of medical research judged not to be compatible with this study
- Have estimated glomerular filtration rate (eGFR) < 60 milliliters per minute per 1.73 square meter (mL/min/1.73 m²) for Parts A and B of this study, or eGFR < 50 mL/min/1.73 m² in Part C only
- For Part C: have a history of severe hypertension (defined as SBP greater than or equal to (≥)180 mmHg and/or DBP ≥120 mmHg), secondary hypertension, symptomatic postural hypotension, or hospitalization due to hypertension
- For Part C: have a history of supraventricular tachycardia (for example, atrial fibrillation), ventricular tachycardia, or other cardiac arrhythmia
- For Part C: have resting tachycardia (heart rate ≥100 beats per minute)
- For Part C: have New York Heart Association (NYHA) Class II, III, or IV heart failure, or had any of the following in the previous 3 months: coronary angioplasty, coronary stent placement, coronary bypass surgery or any significant cardiac surgery, myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack
- For Part C: have an automatic internal cardioverter-defibrillator
- For Part C: have diabetes
Sites / Locations
- PRA Health Sciences
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental
Arm Label
LY3322207 (Part A)
Placebo (Part A)
LY3322207 (Part B)
Placebo (Part B)
LY3322207 (Part C)
Arm Description
LY3322207 administered subcutaneously (SC)
Placebo matching LY3322207 administered SC
LY3322207 administered SC once weekly
Placebo matching LY3322207 administered SC once weekly
LY3322207 administered SC in participants with hypertension
Outcomes
Primary Outcome Measures
Number of Participants with One or More Serious Adverse Events (Part A)
Serious and other non-serious adverse events will be reported in the Adverse Events Module
Number of Participants with One or More Serious Adverse Events (Part B)
Serious and other non-serious adverse events will be reported in the Adverse Events Module
Number of Participants with One or More Serious Adverse Events (Part C)
Serious and other non-serious adverse events will be reported in the Adverse Events Module
Secondary Outcome Measures
Area Under the Concentration Versus Time Curve (AUC) of LY3322207 (Part A)
Pharmacokinetics (PK): AUC of LY3322207
Area Under the Concentration Versus Time Curve (AUC) of LY3322207 (Part B)
PK: AUC of LY3322207
Area Under the Concentration Versus Time Curve (AUC) of LY3322207 (Part C)
PK: AUC of LY3322207
Maximum Concentration (Cmax) of LY3322207 (Part A)
PK: Cmax of LY3322207
Maximum Concentration (Cmax) of LY3322207 (Part B)
PK: Cmax of LY3322207
Maximum Concentration (Cmax) of LY3322207 (Part C)
PK: Cmax of LY3322207
Time to reach Cmax (Tmax) of LY3322207 (Part A)
PK: Tmax of LY3322207
Time to reach Cmax (Tmax) of LY3322207 (Part B)
PK: Tmax of LY3322207
Time to reach Cmax (Tmax) of LY3322207 (Part C)
PK: Tmax of LY3322207
Change from Baseline in Systolic Blood Pressure (SBP) (Part A)
Supine position
Change from Baseline in Systolic Blood Pressure (SBP) (Part B)
Supine position
Change from Baseline in Systolic Blood Pressure (SBP) (Part C)
Supine position
Change from Baseline in Diastolic Blood Pressure (DBP) (Part A)
Supine position
Change from Baseline in Diastolic Blood Pressure (DBP) (Part B)
Supine position
Change from Baseline in Diastolic Blood Pressure (DBP) (Part C)
Supine position
Change from Baseline in Heart Rate (Part A)
Supine position
Change from Baseline in Heart Rate (Part B)
Supine position
Change from Baseline in Heart Rate (Part C)
Supine position
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03590860
Brief Title
A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure)
Official Title
A Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Doses of LY3322207 in Healthy Subjects and Subjects With Hypertension on ACE I/ARB Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Terminated
Why Stopped
injection site reaction burden
Study Start Date
July 13, 2018 (Actual)
Primary Completion Date
January 17, 2019 (Actual)
Study Completion Date
January 17, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
5. Study Description
Brief Summary
The purpose of this study is to investigate the safety of the study drug known as LY3322207. Participants must be healthy or must have hypertension (high blood pressure). Participants with hypertension may already be taking a common drug to reduce blood pressure called an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Part C will be open label
Allocation
Randomized
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LY3322207 (Part A)
Arm Type
Experimental
Arm Description
LY3322207 administered subcutaneously (SC)
Arm Title
Placebo (Part A)
Arm Type
Placebo Comparator
Arm Description
Placebo matching LY3322207 administered SC
Arm Title
LY3322207 (Part B)
Arm Type
Experimental
Arm Description
LY3322207 administered SC once weekly
Arm Title
Placebo (Part B)
Arm Type
Placebo Comparator
Arm Description
Placebo matching LY3322207 administered SC once weekly
Arm Title
LY3322207 (Part C)
Arm Type
Experimental
Arm Description
LY3322207 administered SC in participants with hypertension
Intervention Type
Drug
Intervention Name(s)
LY3322207
Intervention Description
Administered by SC injection
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered by SC injection
Primary Outcome Measure Information:
Title
Number of Participants with One or More Serious Adverse Events (Part A)
Description
Serious and other non-serious adverse events will be reported in the Adverse Events Module
Time Frame
Baseline up to approximately 31 days
Title
Number of Participants with One or More Serious Adverse Events (Part B)
Description
Serious and other non-serious adverse events will be reported in the Adverse Events Module
Time Frame
Baseline up to approximately 9 weeks
Title
Number of Participants with One or More Serious Adverse Events (Part C)
Description
Serious and other non-serious adverse events will be reported in the Adverse Events Module
Time Frame
Baseline up to approximately 9 weeks
Secondary Outcome Measure Information:
Title
Area Under the Concentration Versus Time Curve (AUC) of LY3322207 (Part A)
Description
Pharmacokinetics (PK): AUC of LY3322207
Time Frame
Predose up approximately 31 days
Title
Area Under the Concentration Versus Time Curve (AUC) of LY3322207 (Part B)
Description
PK: AUC of LY3322207
Time Frame
Predose up to approximately 9 weeks
Title
Area Under the Concentration Versus Time Curve (AUC) of LY3322207 (Part C)
Description
PK: AUC of LY3322207
Time Frame
Predose up to approximately 9 weeks
Title
Maximum Concentration (Cmax) of LY3322207 (Part A)
Description
PK: Cmax of LY3322207
Time Frame
Predose up approximately 31 days
Title
Maximum Concentration (Cmax) of LY3322207 (Part B)
Description
PK: Cmax of LY3322207
Time Frame
Predose up to approximately 9 weeks
Title
Maximum Concentration (Cmax) of LY3322207 (Part C)
Description
PK: Cmax of LY3322207
Time Frame
Predose up to approximately 9 weeks
Title
Time to reach Cmax (Tmax) of LY3322207 (Part A)
Description
PK: Tmax of LY3322207
Time Frame
Predose up to approximately Day 31
Title
Time to reach Cmax (Tmax) of LY3322207 (Part B)
Description
PK: Tmax of LY3322207
Time Frame
Predose up to approximately 9 weeks
Title
Time to reach Cmax (Tmax) of LY3322207 (Part C)
Description
PK: Tmax of LY3322207
Time Frame
Predose up to approximately 9 weeks
Title
Change from Baseline in Systolic Blood Pressure (SBP) (Part A)
Description
Supine position
Time Frame
Baseline up approximately 31 days
Title
Change from Baseline in Systolic Blood Pressure (SBP) (Part B)
Description
Supine position
Time Frame
Baseline up to approximately 9 weeks
Title
Change from Baseline in Systolic Blood Pressure (SBP) (Part C)
Description
Supine position
Time Frame
Baseline up to approximately 9 weeks
Title
Change from Baseline in Diastolic Blood Pressure (DBP) (Part A)
Description
Supine position
Time Frame
Baseline up approximately 31 days
Title
Change from Baseline in Diastolic Blood Pressure (DBP) (Part B)
Description
Supine position
Time Frame
Baseline up to approximately 9 weeks
Title
Change from Baseline in Diastolic Blood Pressure (DBP) (Part C)
Description
Supine position
Time Frame
Baseline up to approximately 9 weeks
Title
Change from Baseline in Heart Rate (Part A)
Description
Supine position
Time Frame
Baseline up approximately 31 days
Title
Change from Baseline in Heart Rate (Part B)
Description
Supine position
Time Frame
Baseline up to approximately 9 weeks
Title
Change from Baseline in Heart Rate (Part C)
Description
Supine position
Time Frame
Baseline up to approximately 9 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy males, as determined by medical history and physical examination, must agree to use a medically appropriate method of birth control and agree not to donate sperm from start of dosing until 90 days beyond last dose
Healthy females, as determined by medical history and physical examination, of non-child bearing potential due to:
Menopause: spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications that induced the amenorrhea (for example: oral contraceptives, hormones, gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators, or chemotherapy)
Surgical sterilization
Are reliable and willing to make themselves available for the duration of the study and are willing to follow site specific study procedures
Have a Body Mass Index (BMI) 18 to 30 kilogram per square meter (kg/m²) at entry
Have clinical laboratory test results within normal reference range for the population or site, or results with acceptable deviations that are judged not clinically significant
Be 18 to 55 years old for either Part A or Part B of the study, or 18 to 65 years old for Part C only
For Part C: must have been treated with a stable dose of ACE-I or ARB for at least 1 month
Exclusion Criteria:
Are currently enrolled in, or discontinued within the last 60 days from, a clinical trial involving an investigational drug that has not received regulatory approval
Have previously completed or withdrawn from this study or any other study investigating this study drug
Have a history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, significant atopy, or any clinically significant laboratory abnormality that would preclude study participation
Have abnormality in the 12-lead electrocardiogram (ECG) which increases study risk
Have confirmed QT interval corrected by Bazett's method (QTcB) or Fridericia's (QTcF) method >450 millisecond (msec) for men and >470 msec for women
Have prior Q-wave myocardial infarction or other, specific heart abnormalities, arrhythmias or fibrillations
Have an abnormal blood pressure (supine) defined as diastolic blood pressure greater than (>)95 or less than (<)50 millimeters of mercury (mmHg) and/or systolic blood pressure >160 or <90 mmHg
Show evidence of human immunodeficiency virus (HIV), hepatitis C, or hepatitis B
Have donated blood of more than 100 mL (milliliters) within the last month
Are unwilling to stop alcohol consumption while resident in the Clinical Research Unit
Have an average weekly alcohol intake that exceeds 21 units per week (1 unit equal to (=) 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
Have an abnormal blood pressure (supine) defined as diastolic blood pressure >95 or <50 mmHg and/or systolic blood pressure >160 or <90 mmHg
Have serum potassium outside normal range
Have had lymphoma, leukemia, or any malignancy within the past 5 years
Have clinically significant multiple or severe drug allergies or intolerance
Are lactating women
Positive findings for known drugs of abuse
Have received treatment with biologic agents within 3 months or 5 half-lives prior to dosing
Participation in any other clinical trial involving a study drug or off-label use of a drug or device, or any other type of medical research judged not to be compatible with this study
Have estimated glomerular filtration rate (eGFR) < 60 milliliters per minute per 1.73 square meter (mL/min/1.73 m²) for Parts A and B of this study, or eGFR < 50 mL/min/1.73 m² in Part C only
For Part C: have a history of severe hypertension (defined as SBP greater than or equal to (≥)180 mmHg and/or DBP ≥120 mmHg), secondary hypertension, symptomatic postural hypotension, or hospitalization due to hypertension
For Part C: have a history of supraventricular tachycardia (for example, atrial fibrillation), ventricular tachycardia, or other cardiac arrhythmia
For Part C: have resting tachycardia (heart rate ≥100 beats per minute)
For Part C: have New York Heart Association (NYHA) Class II, III, or IV heart failure, or had any of the following in the previous 3 months: coronary angioplasty, coronary stent placement, coronary bypass surgery or any significant cardiac surgery, myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack
For Part C: have an automatic internal cardioverter-defibrillator
For Part C: have diabetes
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
PRA Health Sciences
City
Groningen
ZIP/Postal Code
9728 NZ
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure)
We'll reach out to this number within 24 hrs